Abstract

Objectives: A systematic review process was adopted to derive more robust estimates of the diagnostic accuracy of 18F-fluorodeoxyglucose(18F-FDG) positron emission tomography /computed tomography (PET/CT) for prostate cancer we pooled published studies. Methods: A comprehensive literature search about published studies till November 2017 was performed. Methodological quality of each study was assessed. A meta-analysis was used to analyze the sensitivity, specificity, diagnostic odds ratio (DOR), area under the curve (AUC), summary receiver operating characteristic (sROC) curve and Ca* indexes with statistical software. Results: Ten articles including 364 patients and 505 lesions, which published between 2009 and 2017, met the inclusion criteria for the meta-analysis. The pooled sensitivity and specificity of 18F-FDG PET-CT in prostatic cancer were 0.65 (95% CI, 0.47-0.79) and 0.85 (95% CI, 0.71-0.93), respectively. The overall PLR, NLR and DOR were 4.3 (95% CI, 2.0-9.2), 0.41 (95% CI, 0.25-0.68) and 10 (95% CI, 3-32), respectively. The area under the summary ROC curve was 0.84. There is not exist publication bias in the included studies according to the Deek’s test. Conclusions: The results of our meta-analysis suggested that 18F-FDG PET-CT were imaging methods with high accuracy in differential diagnosis of prostate cancer patients.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.